Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2023

The Pharma Closeout tracks 61 deals, $227.2B in disclosed deal value, 33 with a post-close Outcome Score for the year 2023.

Median Critic Score: 83  ·  Median Outcome Score: 69

Best outcome: Summit Therapeutics plc / Akeso Inc. (79)  ·  Weakest outcome: Novo Nordisk A/S / KBP Biosciences (26)

All 61 deals

• Summit Therapeutics plc / Akeso Inc. — 2023 · $4.5B · Worked — the deal delivered on its rationale.
• Novartis AG / Chinook Therapeutics Inc. — 2023 · $3.5B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / CinCor Pharma Inc. — 2023 · $1.8B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Prometheus Biosciences Inc. — 2023 · $10.8B · Worked — the deal delivered on its rationale.
• Danaher Corporation / Abcam PLC — 2023 · $5.7B · Worked — the deal delivered on its rationale.
• Pfizer Inc. / Seagen Inc. — 2023 · $43.0B · Worked — the deal delivered on its rationale.
• Bristol-Myers Squibb Company / Karuna Therapeutics — 2023 · $14.0B · Worked — the deal delivered on its rationale.
• GSK plc / Hansoh Pharmaceutical Group Co. Ltd. — 2023 · $1.7B · Largely worked — most objectives met.
• Biogen Inc. / Reata Pharmaceuticals — 2023 · $7.3B · Largely worked — most objectives met.
• Roche Holding AG / Telavant Holdings — 2023 · $7.1B · Largely worked — most objectives met.
• Roche Holding AG / Alnylam Pharmaceuticals Inc. — 2023 · $2.8B · Largely worked — most objectives met.
• Chiesi Farmaceutici S.p.A. / Amryt Pharma plc — 2023 · $1.5B · Largely worked — most objectives met.
• Roche Holding AG / Carmot Therapeutics Inc. — 2023 · $2.7B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / SystImmune Inc. — 2023 · $8.4B · Largely worked — most objectives met.
• Sanofi SA / Provention Bio Inc. — 2023 · $2.9B · Largely worked — most objectives met.
• Novartis AG / Legend Biotech Corporation — 2023 · $1.1B · Largely worked — most objectives met.
• AbbVie Inc. / ImmunoGen Inc. — 2023 · $10.1B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / RayzeBio Inc. — 2023 · $4.1B · Largely worked — most objectives met.
• Merck & Co. Inc. / Daiichi Sankyo Company, Limited — 2023 · $22.0B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / Mirati Therapeutics — 2023 · $4.8B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / Evotec SE — 2023 · $4.0B · Largely worked — most objectives met.
• AstraZeneca PLC / Gracell Biotechnologies — 2023 · $1.2B · Largely worked — most objectives met.
• Eli Lilly and Company / Versanis Bio — 2023 · $1.9B · Largely worked — most objectives met.
• Merck & Co. Inc. / Proxygen GmbH — 2023 · $2.5B · Largely worked — most objectives met.
• Eli Lilly and Company / Point Biopharma — 2023 · $1.4B · Largely worked — most objectives met.
• Novo Nordisk A/S / Inversago Pharma — 2023 · $1.1B · Largely worked — most objectives met.
• AstraZeneca PLC / Icosavax Inc. — 2023 · $1.1B · Largely worked — most objectives met.
• Swedish Orphan Biovitrum AB / CTI BioPharma Corp. — 2023 · $1.7B · Largely worked — most objectives met.
• AstraZeneca PLC / Absci Corporation — 2023 · $247M · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / DICE Therapeutics Inc. — 2023 · $2.4B · Mixed — partial payoff, real shortfalls.
• Immunome Inc. / Morphimmune Inc. — 2023 · $125M · Mixed — partial payoff, real shortfalls.
• AbbVie Inc. / Cerevel Therapeutics — 2023 · $8.7B · Underwhelmed — fell short of the thesis.
• Novo Nordisk A/S / KBP Biosciences — 2023 · $1.3B · Did not work — the deal failed to deliver.
• AstraZeneca PLC / Quell Therapeutics Limited — 2023 · $2.1B
• Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG — 2023 · $330M
• Boehringer Ingelheim International GmbH / T3 Pharmaceuticals AG — 2023 · $508M
• Merck & Co. Inc. / Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — 2023 · $9.5B
• Sanofi SA / BioMap Holdings Limited — 2023 · $1.0B
• AbbVie Inc. / Mitokinin, Inc. — 2023 · $655M
• BioNTech SE / Duality Biologics (Suzhou) Co. Ltd. — 2023 · $1.7B
• Takeda Pharmaceutical Company Limited / HUTCHMED (China) Limited — 2023 · $1.1B
• F. Hoffmann-La Roche AG / Ionis Pharmaceuticals, Inc. — 2023 · $760M
• AstraZeneca PLC / LaNova Medicines Limited — 2023 · $600M
• Boehringer Ingelheim International GmbH / Ginkgo Bioworks Holdings, Inc. — 2023 · $405M
• Novartis AG / Voyager Therapeutics Inc. — 2023 · $1.3B
• AstraZeneca PLC / Cellectis SA — 2023 · $605M
• Eli Lilly and Company / Beam Therapeutics Inc. — 2023 · $600M
• Bristol-Myers Squibb Company / Tubulis GmbH — 2023 · $1.0B
• Sanofi SA / Maze Therapeutics, Inc. — 2023 · $750M
• AstraZeneca PLC / Eccogene (Shanghai) Co., Ltd. — 2023 · $2.0B
• GSK plc / SCYNEXIS, Inc. — 2023 · $593M
• Eli Lilly and Company / Sigilon Therapeutics Inc. — 2023 · $310M
• Ironwood Pharmaceuticals, Inc. / VectivBio Holding AG — 2023 · $1.0B
• Sanofi SA / Teva Pharmaceutical Industries Ltd. — 2023 · $1.5B
• GSK plc / Bellus Health Inc. — 2023 · $2.0B
• Eli Lilly and Company / Mablink Bioscience SAS — 2023 · $250M
• Novo Nordisk A/S / Aspect Biosystems Ltd. — 2023 · $2.7B
• Pfizer Inc. / Nona Biosciences (Harbour BioMed subsidiary) — 2023 · $1.1B
• Sanofi SA / Janssen Pharmaceuticals, Inc. (Johnson & Johnson) — 2023 · $175M
• AbbVie Inc. / Aldeyra Therapeutics, Inc. — 2023 · $400M
• Novo Nordisk A/S / Valo Health, Inc. — 2023 · $4.8B

← Deal Library  ·  Interactive search  ·  How we score deals